Skin & Allergy News

Herpes reactivation increases with TNF-blocking agents.(Clinical Rounds)

BARCELONA -- The risk of reactivation of herpesvirus infection is increased among patients with rheumatoid arthritis who are treated with the antitumor necrosis factor agents, and especially with the monoclonal antibodies infliximab and adalimumab, Dr. Anja Strangfeld said at the annual European Congress of Rheumatology.

"An increased risk of bacterial infections during treatment with the TNF-blocking drugs is well documented, but less attention has been paid to viral infection and reactivation in this regard, so we analyzed data from the German biologics register to ascertain the incidence and risk factors for reactivation of herpesvirus infection," said Dr. Strangfeld, who is an epidemiologist with the German Rheumatism Research Center, Berlin. …

Log in to your account to read this article – and millions more.